ATIM-10. PHASE I/II TRIAL OF RADIATION THERAPY, TEMOZOLOMIDE AND PEMBROLIZUMAB FOLLOWED BY TEMOZOLOMIDE AND PEMBROLIZUMAB IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA

  • Dixit K
  • Kumthekar P
  • Kruser T
  • et al.
N/ACitations
Citations of this article
10Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

BACKGROUND: Patients with glioblastoma (GBM) have a poor prognosis despite maximal resection, and standard of care radiation (RT) with temozolomide (TMZ) [SOC]. Immune checkpoint inhibitors have shown antitumor activity in solid tumors and Hodgkin’s lymphoma. GBM have been shown to express programmed cell death ligand-1 (PD-L1) with anti-tumor activity demonstrated in animal models. A single arm phase I/II trial was done to determine the safety and efficacy of pembrolizumab (anti PD-1 monoclonal antibody) in combination with SOC in newly diagnosed GBM patients. Phase I data are presented.METHODS: Standard adult eligibility criteria were used but > 25% resection was required. Patients received pembrolizumab (200mg intravenously every 3 weeks) starting on day 1 of RT+TMZ with plans for dose de-escalation if a DLT occurred in cohort 1. The DLT window was 9 weeks from the start of RT. Treatment then consisted of pembrolizumab every 3 weeks along with TMZ (9 week cycles). The primary endpoint was maximum tolerated dose (MTD) and determine the recommended phase 2 dose (RP2D).RESULTS: Four patients with GBM were treated (3 men, 1 woman). Median age was 64 (range 39–67) and median KPS was 90 (range 80–100). The most common toxicities were leukopenia (grade 2, n = 2; grade 1, n = 2), anemia (grade 1, n = 4), and fatigue (grade 1, n = 2). There were no grade 3 or 4 toxicities or interruptions in treatment. One patient withdrew without toxicity. The remaining 3 patients are alive and still on treatment having completed 3, 2, and 1 cycles post-RT thus far.CONCLUSION: The combination of pembrolizumab at 200mg added to SOC in patients with newly diagnosed GBM seems to be tolerable. No immune related adverse events were seen in 4 subjects receiving the combination. The RP2D is 200mg every three weeks.

Cite

CITATION STYLE

APA

Dixit, K., Kumthekar, P., Kruser, T., Bloch, O., Chandler, J., Tate, M., & Raizer, J. (2016). ATIM-10. PHASE I/II TRIAL OF RADIATION THERAPY, TEMOZOLOMIDE AND PEMBROLIZUMAB FOLLOWED BY TEMOZOLOMIDE AND PEMBROLIZUMAB IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA. Neuro-Oncology, 18(suppl_6), vi19–vi19. https://doi.org/10.1093/neuonc/now212.075

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free